Published in Cancer Biol Ther on September 25, 2003
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer (2007) 3.28
Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene (2011) 1.33
Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol (2010) 1.17
RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. Exp Hematol (2007) 0.95
Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS One (2011) 0.87
Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis. PLoS One (2011) 0.80
Multifaceted interactions and regulation between antizyme and its interacting proteins cyclin D1, ornithine decarboxylase and antizyme inhibitor. Oncotarget (2015) 0.76
Molecular characteristics of cancer stem-like cells derived from human breast cancer cells. Anticancer Res (2013) 0.75
The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression. Cancer Cell Int (2014) 0.75
Aldehyde dehydrogenase 1A1 increases NADH levels and promotes tumor growth via glutathione/dihydrolipoic acid-dependent NAD(+) reduction. Oncotarget (2017) 0.75
Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol (2004) 15.15
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene (2003) 2.02
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol (2012) 1.84
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res (2007) 1.81
Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res (2004) 1.68
A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst (2005) 1.67
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A (2007) 1.61
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61
Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res (2002) 1.61
A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. J Exp Med (2011) 1.41
Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol (2005) 1.30
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol (2009) 1.26
G0S2 is an all-trans-retinoic acid target gene. Int J Oncol (2008) 1.23
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res (2004) 1.16
UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2002) 1.16
Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem (2004) 1.14
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res (2009) 1.10
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther (2008) 1.09
Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem (2007) 1.07
Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res (2011) 1.05
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res (2007) 1.04
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene (2003) 1.04
High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res (2009) 0.99
Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila) (2010) 0.99
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther (2008) 0.98
Anaphase catastrophe is a target for cancer therapy. Clin Cancer Res (2011) 0.97
Involvement of microRNAs in lung cancer biology and therapy. Transl Res (2011) 0.96
Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Res (2010) 0.96
Cyclin D1 as a target for chemoprevention. Lung Cancer (2003) 0.95
Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res (2004) 0.95
UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther (2008) 0.94
Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene (2002) 0.92
Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. BMC Cancer (2009) 0.92
Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta (2005) 0.91
Lung cancer prevention: the guidelines. Chest (2003) 0.91
Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther (2012) 0.91
Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer (2013) 0.90
Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst (2007) 0.89
Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res (2005) 0.89
Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities. ScientificWorldJournal (2009) 0.87
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood (2013) 0.85
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Lung Cancer (2010) 0.84
Effects of continued tobacco use during treatment of lung cancer. Expert Rev Anticancer Ther (2010) 0.83
The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst (2006) 0.83
Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res (2007) 0.82
Repression of cyclin D1 as a target for germ cell tumors. Int J Oncol (2007) 0.82
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther (2013) 0.80
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol (2012) 0.80
Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy. Endocr Metab Immune Disord Drug Targets (2008) 0.80
Retinoid chemoprevention trials: cyclin D1 in the crosshairs. Cancer Prev Res (Phila) (2009) 0.79
Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst (2004) 0.78
Gene profiling uncovers retinoid target genes. Methods Mol Biol (2007) 0.78
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy (2012) 0.78
Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer (2005) 0.78
Repression of exogenous gene expression by the retinoic acid target gene G0S2. Int J Oncol (2013) 0.77
Clinical link between p53 and angiogenesis in lung cancer. J Clin Oncol (2002) 0.77
Combining cytotoxic chemotherapy with cyclooxygenase-2 inhibition. J Clin Oncol (2003) 0.75
Tissue microarrays for hypothesis generation. J Natl Cancer Inst (2004) 0.75